Abstract
Quinolones are currently the most commonly used group of antimicrobial agents in Norwegian aquaculture. The aims of this study were to examine and compare the pharmacokinetic properties of the quinolones oxolinic acid, flumequine, sarafloxacin, and enrofloxacin after intravascular and oral administration to Atlantic salmon (Salmo salar) by using identical experimental designs. The study was performed in seawater at 10.2 +/- 0.2 degree C with Atlantic salmon weighing 240 +/- 50 g (mean +/- standard deviation). The bioavailability varied considerably among the four quinolones. Following oral administration of medicated feed, the bioavailabilities of oxolinic acid, flumequine, sarafloxacin, and enrofloxacin were 30.1, 44.7, 2.2, and 55.5%, respectively. Taking the different dosages (25 mg/kg of body weight for oxolinic acid and flumequine and 10 mg/kg for sarafloxacin and enrofloxacin) into account, enrofloxacin showed the highest maximum concentration in plasma, followed by flumequine, oxolinic acid, and sarafloxacin. Following intravenous administration, the volumes of distribution at steady state of oxolinic acid, flumequine, sarafloxacin, and enrofloxacin were 5.4, 3.5, 2.3, and 6.1 liters/kg, respectively. Hence, all the quinolones showed good tissue penetration in Atlantic salmon. The elimination half-life of three of the quinolones, oxolinic acid, flumequine, and sarafloxacin, was less than or equal to 24 h, with oxolinic acid showing the shortest (18.2 h). On the other hand, the elimination half-life of enrofloxacin was estimated to be 34.2 h, almost twice that of oxolinic acid. This study showed that flumequine and enrofloxacin had better pharmacokinetic properties, compared with those of oxolinic acid, in Atlantic salmon held in seawater.
Full Text
The Full Text of this article is available as a PDF (204.9 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Barnes A. C., Lewin C. S., Hastings T. S., Amyes S. G. In vitro activities of 4-quinolones against the fish pathogen Aeromonas salmonicida. Antimicrob Agents Chemother. 1990 Sep;34(9):1819–1820. doi: 10.1128/aac.34.9.1819. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Blaser J., Stone B. B., Groner M. C., Zinner S. H. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother. 1987 Jul;31(7):1054–1060. doi: 10.1128/aac.31.7.1054. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bowser P. R., Wooster G. A., St Leger J., Babish J. G. Pharmacokinetics of enrofloxacin in fingerling rainbow trout (Oncorhynchus mykiss). J Vet Pharmacol Ther. 1992 Mar;15(1):62–71. doi: 10.1111/j.1365-2885.1992.tb00987.x. [DOI] [PubMed] [Google Scholar]
- Martinsen B., Oppegaard H., Wichstrøm R., Myhr E. Temperature-dependent in vitro antimicrobial activity of four 4-quinolones and oxytetracycline against bacteria pathogenic to fish. Antimicrob Agents Chemother. 1992 Aug;36(8):1738–1743. doi: 10.1128/aac.36.8.1738. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rasmussen K. E., Tønnesen F., Thanh H. H., Rogstad A., Aanesrud A. Solid-phase extraction and high-performance liquid chromatographic determination of flumequine and oxolinic acid in salmon plasma. J Chromatogr. 1989 Nov 24;496(2):355–364. doi: 10.1016/s0378-4347(00)82583-9. [DOI] [PubMed] [Google Scholar]
- Sörgel F., Jaehde U., Naber K., Stephan U. Pharmacokinetic disposition of quinolones in human body fluids and tissues. Clin Pharmacokinet. 1989;16 (Suppl 1):5–24. doi: 10.2165/00003088-198900161-00004. [DOI] [PubMed] [Google Scholar]
- Vancutsem P. M., Babish J. G., Schwark W. S. The fluoroquinolone antimicrobials: structure, antimicrobial activity, pharmacokinetics, clinical use in domestic animals and toxicity. Cornell Vet. 1990 Apr;80(2):173–186. [PubMed] [Google Scholar]
- Yamaoka K., Nakagawa T., Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm. 1978 Apr;6(2):165–175. doi: 10.1007/BF01117450. [DOI] [PubMed] [Google Scholar]